Choosing neurodegeneration antibodies by the species of the protein that matters: why a tau antibody has to state whether it detects total protein, a phosphorylated epitope or an aggregated conformation, what an fus antibody, an smn antibody, an fmrp antibody and a tmem106b antibody demand of extraction when the target partitions into an insoluble fraction, how a bace1 antibody reports processing rather than amyloid, where a trem2 antibody, a cx3cr1 antibody, a tmem119 antibody and an aldh1l1 antibody mark glial identity and are lost or gained on activation, what a p75 antibody, a p75ntr antibody, an ngfr antibody and an ngf antibody report as the same receptor family under different names, and why an htra1 antibody and a galc antibody sit with the same insolubility problem

Designing the extraction and the panel

1. Fractionate by solubility deliberately. Sequential extraction into soluble and insoluble fractions is the core technique here, because the pathological species partitions into the fraction most protocols discard. Blot both and show both.
2. Name the species the reagent detects. Total, phosphorylated at a defined site, conformational and truncated reagents exist for the same protein and report different things. Buy against the species in the hypothesis, and say which in the methods.
3. Preserve modification state at collection. Phosphorylation is lost quickly post mortem and in a warm lysate. Handling time, temperature and inhibitor presence dominate the measurement of any phosphorylated species.
4. Read glial markers as state dependent. Markers used to identify glial populations change with activation, so a reduced signal can mean fewer cells or a changed state. Pair an identity marker with a state marker before drawing a conclusion about numbers.
5. Confirm aggregates by more than a blot. Insolubility on a blot is suggestive; a conformation specific reagent, a filter trap assay or imaging of inclusions is what supports an aggregation claim.

Solubility is the axis

The organising principle of this field is that proteins move from a soluble, functional pool into an insoluble, aggregated one. Every technical decision, extraction buffer, centrifugation, whether the pellet is analysed, follows from that.

Report both fractions and the extraction conditions. A result from one fraction with no description of the other is uninterpretable to anyone trying to reproduce it.

Post mortem tissue is its own discipline

Interval to fixation, agonal state and storage all change what is measurable, particularly for modified species. Those variables frequently exceed the disease effect being studied.

Record them for every case, match them between groups, and treat them as covariates. Studies that do this reproduce; studies that do not, generally do not.

Common questions

Why is my target absent from the lysate?

Because it went into the pellet. In this field the insoluble fraction is frequently the sample that matters, and a protocol that discards it will report a loss where there was a redistribution.

Total or phospho reagent?

Both, from the same sample. The phosphorylated species is only interpretable as a fraction of the total, and treatments and disease states change both.

Does a glial marker count cells?

Only if the marker is state independent, which most are not. Activation changes expression, so an apparent change in cell number may be a change in phenotype. Use two markers with different regulation.

Browse by service class

• Compare Gene synthesis on advertised prices